General Dermatology

Noor, the co-owner of Rao Dermatology, shares about his interests in dermatology and what he most looks forward to as a member of our board.

In this week’s Pointers With Portela, the 208SkinDoc discusses the effectiveness of a minimalist anti-aging skin care routine for patients.

Researchers recently developed and validated the 3-question social comparison scale, which may be applicable outside of conditions such as eczema and psoriasis.

Addressing gender inequity in academic dermatology involves strengthening societies, celebrating female dermatologists, promoting leadership, and equitable representation, authors wrote.

The WHO underscores the significance of addressing scabies as a neglected skin disease, especially in regions with limited health care access.

Interim findings from the PROSPER study of mogamulizumab in adults with CTCL were recently presented orally.

Research from the GW School of Medicine and Health Sciences was recently published in the Journal of Drugs in Dermatology.

Dermatology Times is pleased to introduce one of our newest partners, Spherix Global Insights. Learn more about their vision and plans to leverage knowledge to support dermatology.

Keep up with the latest headlines in dermatology from the past week, including UK efforts to address skin cancer disparities in skin of color, efficacy of a "virtual biopsy," and more.

ICYMI, this week we had news about Rosacea Awareness Month, topical pravibismane in diabetic foot ulcer infections, and more.

Dermatology Times is pleased to introduce our Spring Editor in Chief, Aaron Farberg, MD, with a snapshot of his involvement in the dermatology space.

This week’s collection of the latest dermatologic studies covers circulating tumor DNA in advanced cSCC, targeting IL-13 with tralokinumab in AD, a pediatric lymphoplasmocytic plaque case report, and skin of color reporting in randomized controlled trials focusing on SCC.

In an introduction to our April publication, explore an overview of topics covered in this issue and an introduction to our Spring Editor in Chief, Aaron Farberg, MD.

Data was recently published in the International Wound Journal supporting positive outcomes in moderate or severe ulcers.

Keep up with the latest headlines in dermatology from the past week, including the launch of an expanded job board for dermatology support roles, CMS and Incyte's collaboration for povorcitinib in China and Southeast Asia, and more.

ICYMI, this week we had news about Ycanth's J-code launch, highlights from Diversity in Dermatology, bimekizumab's accepted sBLA for HS, and more.

Gil Yosipovitch, MD, discusses the correlation between increased BNP levels and chronic pruritus of unknown origin.

In a comparative study, benzyl benzoate demonstrated superior efficacy in scabies cases, while topical permethrin exhibited a lack of effectiveness.

Researchers reviewed the efficacy and safety of omalizumab in patients with severe CSU in a routine clinical practice setting.

This week’s collection of the latest dermatologic studies covers topical permethrin 5% vs. benzyl benzoate 25% for scabies, the safety of omalizumab in CSU during pregnancy, symptoms of cognitive impairment in children with AD, and the ethics of cosmetic overtreatment.

In this study, topical 0.1% retinol significantly improved crow’s feet, facial wrinkles, uneven skin tone, brown spots, and overall photoaging.

In this week’s Pointers With Portela, the 208SkinDoc reviews how the skin is affected during hormonal changes and menopause.

The new launch is set to bring berdazimer topical gel, 10.3% to adults and pediatric patients over the age of 1 with molluscum contagiosum faster.

The agreement for a second confirmatory trial comes after a successful phase 3 FLASH study that yielded positive outcomes and efficacy.

Shah discusses the science behind his products, as well as the challenges he didn’t anticipate when launching Remedy.

The biosimilar landscape experienced significant activity, marked by fresh data from conferences, novel findings regarding adalimumab biosimilars, and more.

Shahriari shares pearls and considerations from her sessions at the recent Diversity in Dermatology conference.

Povorcitinib is being evaluated for non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, asthma, and chronic spontaneous urticaria.

The permanent J-code for the molluscum contagiosum treatment is now live.

ICYMI, this week we had news about bringing awareness to ethics in aesthetics, the 7 year anniversary of dupilumab's approval for atopic dermatitis, and more.